이규형 교수
#골수이식#골수구성백혈병#재생불량성빈혈#EBS명의#헬스조선명의
|
학력
1991 .09 ~ 1994 .08가톨릭대학교 의학 박사
1989 .09 ~ 1991 .08가톨릭대학교 의학 석사
1976 .03 ~ 1982 .02서울대학교 의학 학사
1989 .09 ~ 1991 .08가톨릭대학교 의학 석사
1976 .03 ~ 1982 .02서울대학교 의학 학사
경력
2010 .03 ~ 2014 .02울산의대 서울아산병원 내과 과장 및 주임교수
2008 .01 ~ 2010 .03울산의대 서울아산병원 암센터소장
2006 .03 ~ 2008 .01울산의대 서울아산병원 PI실장
2004 .03 ~ 2010 .02울산의대 서울아산병원 혈액내과 과장
2001 .03 ~ 현재울산의대 서울아산병원 혈액내과 교수
1996 .04 ~ 2001 .02울산의대 서울아산병원 종양혈액내과 부교수
1992 .04 ~ 1996 .03울산의대 서울아산병원 종양혈액내과 조교수
1989 .03 ~ 1992 .03울산의대 서울아산병원 종양혈액내과 전임강사
1988 .07 ~ 1989 .02미국 텍사스 MD Anderson 암센터 Junior Faculty Associate
1986 .07 ~ 1988 .06미국 텍사스 MD Anderson 암센터 종양학 전임의
1983 .07 ~ 1986 .06미국 오하이오 Wright 주립의대 내과 전공의
1982 .07 ~ 1983 .06미국 메사츄세츠 Saint Vincent 병원 병리학 전공의
2008 .01 ~ 2010 .03울산의대 서울아산병원 암센터소장
2006 .03 ~ 2008 .01울산의대 서울아산병원 PI실장
2004 .03 ~ 2010 .02울산의대 서울아산병원 혈액내과 과장
2001 .03 ~ 현재울산의대 서울아산병원 혈액내과 교수
1996 .04 ~ 2001 .02울산의대 서울아산병원 종양혈액내과 부교수
1992 .04 ~ 1996 .03울산의대 서울아산병원 종양혈액내과 조교수
1989 .03 ~ 1992 .03울산의대 서울아산병원 종양혈액내과 전임강사
1988 .07 ~ 1989 .02미국 텍사스 MD Anderson 암센터 Junior Faculty Associate
1986 .07 ~ 1988 .06미국 텍사스 MD Anderson 암센터 종양학 전임의
1983 .07 ~ 1986 .06미국 오하이오 Wright 주립의대 내과 전공의
1982 .07 ~ 1983 .06미국 메사츄세츠 Saint Vincent 병원 병리학 전공의
논문
Prognostic impact of lymphocyte subpopulations in peripheral blood after hematopoietic stem cell transplantation for hematologic malignancies.
The detailed kinetics of cytomegalovirus-specific T cell responses after hematopoietic stem cell transplantation: 1 year follow-up data.
Allogeneic hematopoietic cell transplantation for lymphoma: baseline and posttransplant prognostic factors.
Clinical characteristics and outcomes of patients with chronic disseminated candidiasis who need adjuvant corticosteroid therapy.
Prognostic significance of recurrent additional chromosomal abnormalities in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia.
Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Salvage therapy for acute chemorefractory leukemia by allogeneic stem cell transplantation: the Korean experience.
Alterations in the bone marrow microenvironment may elicit defective hematopoiesis: a comparison of aplastic anemia, chronic myeloid leukemia, and normal bone marrow.
An isolated cardiac relapse after allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia.
Biweekly dose-dense gemcitabine-oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial.
Clinical and histopathological analysis of 46 cases of cutaneous adverse reactions to imatinib
Diagnostic usefulness of dynamic changes of CMV-specific T-cell responses in predicting CMV infections in HCT recipients.
Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy.
Donor-Derived Natural Killer Cell Infusion after Human Leukocyte Antigen?Haploidentical Hematopoietic Cell Transplantation in Patients with Refractory Acute Leukemia
Dynamic prognostic value of the revised international prognostic scoring system following pretransplant hypomethylating treatment in myelodysplastic syndrome.
Evaluation of parameters obtained from the Sysmex XN-2000 for predicting the recovery of the absolute neutrophil count and platelets after hematopoietic stem cell transplantation.
Non-myeloablative conditioning for lower-risk myelodysplastic syndrome with bone marrow blasts less than 5%―a feasibility study
Prospective validation of a novel dosing scheme for intravenous busulfan in adult patients undergoing hematopoietic stem cell transplantation.
A Phase II Trial of Fludarabine/Melphalan 100 Conditioning Therapy Followed by Allogeneic Hematopoietic Cell Transplantation for Patients With Lymphoma.
A prospective, multicenter phase II study of continuous infusion of FLAG for patients older than 60혻yr with resistant acute myeloid leukemia: a comparison with intensive younger patients' trial.
Immunophenotypic markers in adult acute lymphoblastic leukemia: the prognostic significance of CD20 and TdT expression.
JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.
Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Monosomal karyotype in acute myeloid leukemia and the role of allogeneic hematopoietic cell transplantation.
Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.
Prognostic role of FEV1 for survival in bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.
Reconstitution of lymphocyte subpopulations after hematopoietic stem cell transplantation: comparison of hematologic malignancies and donor types in event-free patients.
Restrictive chronic lung function decline after haematopoietic stem cell transplantation.
The efficacy of prophylactic azithromycin on bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.
The detailed kinetics of cytomegalovirus-specific T cell responses after hematopoietic stem cell transplantation: 1 year follow-up data.
Allogeneic hematopoietic cell transplantation for lymphoma: baseline and posttransplant prognostic factors.
Clinical characteristics and outcomes of patients with chronic disseminated candidiasis who need adjuvant corticosteroid therapy.
Prognostic significance of recurrent additional chromosomal abnormalities in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia.
Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Salvage therapy for acute chemorefractory leukemia by allogeneic stem cell transplantation: the Korean experience.
Alterations in the bone marrow microenvironment may elicit defective hematopoiesis: a comparison of aplastic anemia, chronic myeloid leukemia, and normal bone marrow.
An isolated cardiac relapse after allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia.
Biweekly dose-dense gemcitabine-oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial.
Clinical and histopathological analysis of 46 cases of cutaneous adverse reactions to imatinib
Diagnostic usefulness of dynamic changes of CMV-specific T-cell responses in predicting CMV infections in HCT recipients.
Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy.
Donor-Derived Natural Killer Cell Infusion after Human Leukocyte Antigen?Haploidentical Hematopoietic Cell Transplantation in Patients with Refractory Acute Leukemia
Dynamic prognostic value of the revised international prognostic scoring system following pretransplant hypomethylating treatment in myelodysplastic syndrome.
Evaluation of parameters obtained from the Sysmex XN-2000 for predicting the recovery of the absolute neutrophil count and platelets after hematopoietic stem cell transplantation.
Non-myeloablative conditioning for lower-risk myelodysplastic syndrome with bone marrow blasts less than 5%―a feasibility study
Prospective validation of a novel dosing scheme for intravenous busulfan in adult patients undergoing hematopoietic stem cell transplantation.
A Phase II Trial of Fludarabine/Melphalan 100 Conditioning Therapy Followed by Allogeneic Hematopoietic Cell Transplantation for Patients With Lymphoma.
A prospective, multicenter phase II study of continuous infusion of FLAG for patients older than 60혻yr with resistant acute myeloid leukemia: a comparison with intensive younger patients' trial.
Immunophenotypic markers in adult acute lymphoblastic leukemia: the prognostic significance of CD20 and TdT expression.
JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.
Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Monosomal karyotype in acute myeloid leukemia and the role of allogeneic hematopoietic cell transplantation.
Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.
Prognostic role of FEV1 for survival in bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.
Reconstitution of lymphocyte subpopulations after hematopoietic stem cell transplantation: comparison of hematologic malignancies and donor types in event-free patients.
Restrictive chronic lung function decline after haematopoietic stem cell transplantation.
The efficacy of prophylactic azithromycin on bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.
저서
저서 내용이 없습니다.
보도자료
자연살해세포, 난치성 암 치료에 효과 입증
https://www.ytn.co.kr/_ln/0115_201404011105067154
“백혈병 환자에 가족 골수 이식한 뒤 자연살해세포 주입 암 재발 절반 줄여”
http://www.seoul.co.kr/news/newsView.php?id=20140402011020
[기고]NK세포치료의 개발 및 실용화를 위한 성공조건
https://www.etnews.com/20210524000162
https://www.ytn.co.kr/_ln/0115_201404011105067154
“백혈병 환자에 가족 골수 이식한 뒤 자연살해세포 주입 암 재발 절반 줄여”
http://www.seoul.co.kr/news/newsView.php?id=20140402011020
[기고]NK세포치료의 개발 및 실용화를 위한 성공조건
https://www.etnews.com/20210524000162
포스팅
Anti-leukemic effects of vosaroxin, an anti-cancer quinolone derivative, on hypomethylating agent resistant cells
The detailed kinetic data on cytomegalovirus (CMV)-specific T cell responses after hematopoietic stem cell transplantation: 1 year follow-up data
Inhibition of DNA methyltransferases by volasertib in HMA resistant cell lines
Treatment outcomes of myelodysplastic syndrome patients relapsing after allogeneic hematopoietic cell transplantation
Intravenous Busulfan-Based Conditioning Regimens in Allogeneic Hematopoietic Cell Transplantation for Patients with Acute Lymphoblastic Leukemia
Prognostic Impact of Mutant Allele Ratio, Not Conferred by Duplicated Fragment Length, of FMS-like Tyrosine Kinase 3 Internal Tandem Duplication in Patients with Acute Myeloid Leukemia
Non-Myeloablative Conditioning for Lower-Risk Myelodysplastic Syndrome with Bone Marrow Blasts less than 5% ? a Feasibility Study
Frequency, Characteristics and Prognostic Significance of RUNX1 Mutations in Patients with Acute Myeloid Leukemia, Not Otherwise Specified
Frequency, Characteristics and Prognostic Significance of RUNX1 Mutations in Patients with Acute Myeloid Leukemia, Not Otherwise Specified
Identification of novel fusion genes and differentially expressed genes in acute leukemia through transcriptome analysis
Expression of JL1 Antigen in Acute Leukemia and Myelodysplastic Syndrome
Bone Marrow Histopathology with Gene Mutational Correlation in Patients with Essential Thrombocythemia and Primary Myelofibrosis
Alternating Appearance of Acute Promyelocytic Leukemia and Secondary Myelodysplastic Syndrome: Case Report
Predictive Value of Post-transplant Molecular Minimal Residual Disease Monitoring Versus Pretreatment Risk Factors in Patients with Favorable Risk Acute Myeloid Leukemia Following Hematopoietic Stem Cell Transplantation
The role of quantitation of PML-RARa fusion transcript in the risk stratification in patients with acute promyelocytic leukemia
Therapy-related Acute Promyelocytic Leukemia: Observations Relating to Incidence, Pathogenesis and Clinicobiologic Features
Changes of Hematopoietic Microenvironment and Lymphocytes in Hematopoietic Stem Cell Transplantation of Acute Lymphoblastic Leukemia: Comparison between Relapse and Non-relapse groups
Simplified Immunophenotyping Panel for Multiple Myeloma to differentiate neoplastic myeloma cells from reactive plasma cells
The detailed kinetic data on cytomegalovirus (CMV)-specific T cell responses after hematopoietic stem cell transplantation: 1 year follow-up data
Inhibition of DNA methyltransferases by volasertib in HMA resistant cell lines
Treatment outcomes of myelodysplastic syndrome patients relapsing after allogeneic hematopoietic cell transplantation
Intravenous Busulfan-Based Conditioning Regimens in Allogeneic Hematopoietic Cell Transplantation for Patients with Acute Lymphoblastic Leukemia
Prognostic Impact of Mutant Allele Ratio, Not Conferred by Duplicated Fragment Length, of FMS-like Tyrosine Kinase 3 Internal Tandem Duplication in Patients with Acute Myeloid Leukemia
Non-Myeloablative Conditioning for Lower-Risk Myelodysplastic Syndrome with Bone Marrow Blasts less than 5% ? a Feasibility Study
Frequency, Characteristics and Prognostic Significance of RUNX1 Mutations in Patients with Acute Myeloid Leukemia, Not Otherwise Specified
Frequency, Characteristics and Prognostic Significance of RUNX1 Mutations in Patients with Acute Myeloid Leukemia, Not Otherwise Specified
Identification of novel fusion genes and differentially expressed genes in acute leukemia through transcriptome analysis
Expression of JL1 Antigen in Acute Leukemia and Myelodysplastic Syndrome
Bone Marrow Histopathology with Gene Mutational Correlation in Patients with Essential Thrombocythemia and Primary Myelofibrosis
Alternating Appearance of Acute Promyelocytic Leukemia and Secondary Myelodysplastic Syndrome: Case Report
Predictive Value of Post-transplant Molecular Minimal Residual Disease Monitoring Versus Pretreatment Risk Factors in Patients with Favorable Risk Acute Myeloid Leukemia Following Hematopoietic Stem Cell Transplantation
The role of quantitation of PML-RARa fusion transcript in the risk stratification in patients with acute promyelocytic leukemia
Therapy-related Acute Promyelocytic Leukemia: Observations Relating to Incidence, Pathogenesis and Clinicobiologic Features
Changes of Hematopoietic Microenvironment and Lymphocytes in Hematopoietic Stem Cell Transplantation of Acute Lymphoblastic Leukemia: Comparison between Relapse and Non-relapse groups
Simplified Immunophenotyping Panel for Multiple Myeloma to differentiate neoplastic myeloma cells from reactive plasma cells
영상자료
[MBN] "골수와 함께 면역력도 이식"…백혈병 생존율 높인다
https://www.mbn.co.kr/pages/vod/programView.mbn?bcastSeqNo=1068206
[KBS] '가족 면역세포'로 혈액암 치료..."생존율 7배 ↑"
https://www.youtube.com/watch?v=5h1XYhZRyfs
https://www.mbn.co.kr/pages/vod/programView.mbn?bcastSeqNo=1068206
[KBS] '가족 면역세포'로 혈액암 치료..."생존율 7배 ↑"
https://www.youtube.com/watch?v=5h1XYhZRyfs
발표자료
골수형성이상증후군 골수생검에서 면역조직화학염색으로 시행한 CD34 및 p53 발현양상과 예후와의 연관성
A Case of Catheter-Related Blood Stream Infection of Tsukamurella pulmonis
JAK2 V617F 돌연변이 음성인 진성적혈구증다증 환자에서 확인된 엑손 12 돌연변이 1예
골수형성이상증후군에서 4색 유세포분석의 진단적 유용성
CD34 및 p53 면역조직화학염색을 이용한 저세포성 골수형성이상증후군과 재생불량성빈혈의 감별진단
Alemtuzumab treatment for aplastic anemia (AA) and low-risk myelodysplastic syndrome (MDS): preliminary results
HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION WITHOUT EX VIVO- T CELL DEPLETION AFTER REDUCED-INTENSITY CONDITIONING OF BUSULFAN, FLUDARABINE, AND ANTI-THYMOCYTE GLOBULIN
C3435T polymorphism of MDR1 gene is not associated with p-glycoprotein function of leukemic blasts and clinical outcomes in patients with acute myeloid leukemia
Preliminary results of a prospective multicenter phase III trial comparing high-dose and standard-dose daunorubicin for induction of complete remission (CR) in acute myeloid leukemia (AML)
급성림프아구성백혈병에서 형태학적 관해 후 유세포분석을 이용한 미세잔존백혈병의 예후인자로서의 의의
CML 환자에서 der(9) 상의 BCR과 ABL 유전자의 결실 빈도 및 임상적, 혈액학적, 세포유전학적, 예후와의 상관성 연구
Prognostic significance of FLT3 mutation in paired initial and relapse marrow samples of acute myeloid leukemia
급성 골수성 백혈병에서 형태학적 관해 후 유세포분석을 이용한 미세잔존백혈병 측정의 의의
골수종을 동반하고 호중구 기능이 증가된 만성호중구성백혈병 1예
급성양표현성백혈병의 혈액학적 양상, 면역표현형 및 세포유전학적 소견이 예후에 미치는 영향
급성 림프구성 백혈병에서 형태학적 관해 후 유세포분석을 이용한 미세잔존백혈병의 예후인자로서의 의의
3q21q26 Syndrome의 혈액학적, 임상적 소견: 매우 불량한 예후와 중추성 요붕증과의 연관성
급성골수성백혈병 환자 612명에서 세포유전학적 아형의 연령 특이적 고찰
A Case of Catheter-Related Blood Stream Infection of Tsukamurella pulmonis
JAK2 V617F 돌연변이 음성인 진성적혈구증다증 환자에서 확인된 엑손 12 돌연변이 1예
골수형성이상증후군에서 4색 유세포분석의 진단적 유용성
CD34 및 p53 면역조직화학염색을 이용한 저세포성 골수형성이상증후군과 재생불량성빈혈의 감별진단
Alemtuzumab treatment for aplastic anemia (AA) and low-risk myelodysplastic syndrome (MDS): preliminary results
HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION WITHOUT EX VIVO- T CELL DEPLETION AFTER REDUCED-INTENSITY CONDITIONING OF BUSULFAN, FLUDARABINE, AND ANTI-THYMOCYTE GLOBULIN
C3435T polymorphism of MDR1 gene is not associated with p-glycoprotein function of leukemic blasts and clinical outcomes in patients with acute myeloid leukemia
Preliminary results of a prospective multicenter phase III trial comparing high-dose and standard-dose daunorubicin for induction of complete remission (CR) in acute myeloid leukemia (AML)
급성림프아구성백혈병에서 형태학적 관해 후 유세포분석을 이용한 미세잔존백혈병의 예후인자로서의 의의
CML 환자에서 der(9) 상의 BCR과 ABL 유전자의 결실 빈도 및 임상적, 혈액학적, 세포유전학적, 예후와의 상관성 연구
Prognostic significance of FLT3 mutation in paired initial and relapse marrow samples of acute myeloid leukemia
급성 골수성 백혈병에서 형태학적 관해 후 유세포분석을 이용한 미세잔존백혈병 측정의 의의
골수종을 동반하고 호중구 기능이 증가된 만성호중구성백혈병 1예
급성양표현성백혈병의 혈액학적 양상, 면역표현형 및 세포유전학적 소견이 예후에 미치는 영향
급성 림프구성 백혈병에서 형태학적 관해 후 유세포분석을 이용한 미세잔존백혈병의 예후인자로서의 의의
3q21q26 Syndrome의 혈액학적, 임상적 소견: 매우 불량한 예후와 중추성 요붕증과의 연관성
급성골수성백혈병 환자 612명에서 세포유전학적 아형의 연령 특이적 고찰